MIT/B12 Compounded Injection Recalled for Sterility Assurance Concerns
Red Mountain Compounding Pharmacy is recalling MIT/B12 25/50/50MG/ML 1MG/ML multidose vials due to FDA inspection findings that raised concerns about the lack of assurance of sterility. The product was distributed to approximately 494 patients across seven states.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II drug recall involving a sterility assurance deficiency in an injectable medication. Although no hospitalizations or illnesses are reported in the source text, lack of sterility in compounded injectables carries significant risk of harm and meets the FDA Class II threshold for severity score 4.
Plain-English summary
Red Mountain Compounding Pharmacy, operating as First Royal Care Co. LLC, is recalling MIT/B12 25/50/50MG/ML 1MG/ML multidose vials (prescription only). The recall is due to lack of assurance of sterility, as identified during an FDA inspection.
The affected product was distributed to approximately 494 patients who received prescriptions located in Arizona, California, Florida, Minnesota, Montana, Texas, and Utah. All lots within their expiration dates are included in this recall.
Patients who have received this product should contact their healthcare provider or dispensing pharmacy for guidance. Sterility assurance issues in injectable medications are serious concerns that can potentially affect patient safety.
The recalled product
- Product
- MIT/B12 25/50/50MG/ML 1MG/ML MDV, Rx only, Red Mountain Compounding Rx
- Manufacturer
- First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy
- Category
- Drug — Compounded Injectable
- Hazard
- sterility-assurance
- contamination-risk
- injection-safety
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- all lots within expiry
Distribution
Distributed in 7 states:
- AZ
- CA
- FL
- MN
- MT
- TX
- UT
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- ModerateGas-X Simethicone 125 mg softgels recall for incomplete labeling
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27